In addition to its utility as a unique resource, integrating our findings with existing molecular profiling datasets allowed us to propose and validate a model where GBM intra-tumor heterogeneity can be defined to exist across a three-dimensional axis defined by their relative MYC-, KRAS- and hypoxia programs. This evidence concerns the gene MYC and glioblastoma.